Get the Stockscreener App
1.40
5.41%
-0.08
In 8 Bio Inc stock is traded at $1.40, with a volume of 60,018.
It is down -5.41% in the last 24 hours and down -17.65% over the past month.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
See More
Previous Close:
$1.48
Open:
$1.455
24h Volume:
60,018
Relative Volume:
0.71
Market Cap:
$13.79M
Revenue:
-
Net Income/Loss:
$-19.44M
P/E Ratio:
-0.5266
EPS:
-2.6585
Net Cash Flow:
$-12.71M
1W Performance:
-13.04%
1M Performance:
-17.65%
6M Performance:
-38.05%
1Y Performance:
-72.98%
1-Day Range:
$1.38
$1.46
1-Week Range:
$1.35
$1.55
52-Week Range:
$1.17
$5.817
In 8 Bio Inc Stock (INAB) Company Profile
Name
In 8 Bio Inc
Sector
Industry
Phone
(646) 600-6438
Address
EMPIRE STATE BUILDING, NEW YORK
Compare INAB vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
1.40 | 13.79M | 0 | -19.44M | -12.71M | -2.6585 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-18-24 | Initiated | Laidlaw | Buy |
| Aug-30-22 | Initiated | H.C. Wainwright | Buy |
In 8 Bio Inc Stock (INAB) Latest News
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - stocktitan.net
Passage Bio Inc Stock: Gene Therapy Innovator Faces Clinical and Funding Hurdles in Competitive Biot - ad-hoc-news.de
Vor Bio (Nasdaq: VOR) secures $75M private placement to fund telitacicept - Stock Titan
[8-K] Instil Bio, Inc. Reports Material Event - Stock Titan
Tela Bio targets at least 8% revenue growth in 2026 while advancing commercial transformation - MSN
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
Upstream Bio (NASDAQ: UPB) establishes $150M at-the-market stock program - Stock Titan
bioAffinity Technologies (BIAF) shares March 2026 investor presentation materials - Stock Titan
Upstream Bio (NASDAQ: UPB) deepens 2025 loss while推进 Phase 3 verekitug strategy - Stock Titan
Tevogen Bio Holdings Inc. Files Form 8-K on NASDAQ: Company Details and Key Information for March 2026 - Minichart
Annovis Bio, Inc. Files Form 8-K with NYSE Listing and Corporate Information for March 23, 2026 - Minichart
Annovis Bio's Mark Guerin departs as CFO; Maria Maccecchini to serve as Acting CFO - TradingView
CFO departs Annovis Bio (ANVS) as CEO Maria Maccecchini takes acting finance role - Stock Titan
Tevogen Bio (TVGN) restores Nasdaq bid-price compliance after 1-for-50 reverse split - Stock Titan
bioAffinity Technologies (BIAF) plans CyPath Lung webinar showcasing real-world clinical use - Stock Titan
TELA Sees Growth with FY26 Revenue Projected to Rise at Least 8% - GuruFocus
TELA Bio (NASDAQ: TELA) lifts 2025 sales 16% but posts $38.8M loss - Stock Titan
Medical device maker secures up to $70M after 18% sales gain - Stock Titan
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. - The Manila Times
INmune Bio will discuss 2025 results and corporate update March 30 - Stock Titan
PALI SEC FilingsPalisade Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cabaletta Bio (NASDAQ: CABA) details 2025 results and advances rese-cel trials - Stock Titan
INB.bio Launches 2026 Growth Strategy With New Market Entries Across Africa, MENA and Southeast Asia - GlobeNewswire Inc.
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
UPB SEC FilingsUpStream Bio Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Palisade Bio Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
TELA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
TELA Bio (TELA) hit with Nasdaq $1 bid-price deficiency, faces delisting risk - Stock Titan
NUVB SEC FilingsNuvation Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event | BPTH SEC FilingForm 8-K - Stock Titan
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
[EFFECT] Gossamer Bio, Inc. SEC Filing - Stock Titan
Passage BIO (PASG) CEO receives 58,000-share stock option grant - Stock Titan
[144] KALA BIO, Inc. SEC Filing - Stock Titan
Gossamer Bio (NASDAQ: GOSS) 2025 loss widens as seralutinib Phase 3 misses goal - Stock Titan
Phase 3 trial push deepens 2025 loss at Annovis Bio (NYSE: ANVS) - Stock Titan
Kyntra Bio (Nasdaq: KYNB) unveils 2025 results, FG-3246 and roxadustat plans - Stock Titan
INmune Bio Receives $8 Consensus Price Target from Analysts - National Today
KRRO SEC FilingsKorro Bio, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
[8-K] Bio Green Med Solution, Inc. Reports Material Event | BGMS SEC FilingForm 8-K - Stock Titan
CyPath Lung growth accelerates while bioAffinity (NASDAQ: BIAF) posts larger 2025 loss - Stock Titan
Morgan Stanley Smith Barney files Form 144 to sell restricted KALA shares (KALA) - Stock Titan
Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan
Korro Bio (NASDAQ: KRRO) expands RNA-editing pipeline as 2025 net loss deepens - Stock Titan
Form 144: Restricted stock sale notice — Kala Pharmaceuticals (NASDAQ: KALA) - Stock Titan
ACET SEC FilingsAdicet Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
BioXcel Therapeutics (NASDAQ: BTAI) completes $7.8M equity and warrant financing - Stock Titan
$180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan
Passage Bio (PASG) pays $4.8M to end long-term Hopewell lab lease - Stock Titan
In 8 Bio Inc Stock (INAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):